An Open-Label, Two-Part, Single Sequence Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2

Trial Profile

An Open-Label, Two-Part, Single Sequence Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Lapatinib (Primary) ; Esomeprazole
  • Indications Advanced breast cancer; Bleeding ulcer; Gastro-oesophageal reflux; Helicobacter pylori infections; NSAID-induced ulcer; Peptic ulcer; Zollinger-Ellison syndrome
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Jul 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 01 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Oct 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top